Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Hontecillas-Prieto L, García-Domínguez DJ, Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Sánchez-León ML, Silva-Romeiro S, Flores-Campos R, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, Provencio-Pulla M, Sánchez-Beato M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Rueda-Domínguez A, Sánchez-Margalet V, de la Cruz-Merino L. Hontecillas-Prieto L, et al. Among authors: alvaro naranjo t. Front Immunol. 2024 Feb 26;15:1293931. doi: 10.3389/fimmu.2024.1293931. eCollection 2024. Front Immunol. 2024. PMID: 38469299 Free PMC article. Clinical Trial.
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Palazón-Carrión N, Martín García-Sancho A, Nogales-Fernández E, Jiménez-Cortegana C, Carnicero-González F, Ríos-Herranz E, de la Cruz-Vicente F, Rodríguez-García G, Fernández-Álvarez R, Martínez-Banaclocha N, Gumà-Padrò J, Gómez-Codina J, Salar-Silvestre A, Rodríguez-Abreu D, Gálvez-Carvajal L, Labrador J, Guirado-Risueño M, García-Domínguez DJ, Hontecillas-Prieto L, Espejo-García P, Fernández-Román I, Provencio-Pulla M, Sánchez-Beato M, Navarro M, Marylene L, Álvaro-Naranjo T, Casanova-Espinosa M, Sánchez-Margalet V, Rueda-Domínguez A, de la Cruz-Merino L. Palazón-Carrión N, et al. Among authors: alvaro naranjo t. Clin Cancer Res. 2022 Sep 1;28(17):3658-3668. doi: 10.1158/1078-0432.CCR-22-0588. Clin Cancer Res. 2022. PMID: 35727601 Free PMC article. Clinical Trial.
The complexity of cancer immunotherapy illustrated through skin tumors.
Vieco-Martí I, López-Carrasco A, de la Cruz-Merino L, Noguera R, Álvaro Naranjo T. Vieco-Martí I, et al. Among authors: alvaro naranjo t. Int J Biol Markers. 2022 Jun;37(2):113-122. doi: 10.1177/03936155221088884. Epub 2022 Apr 27. Int J Biol Markers. 2022. PMID: 35473449 Free article.
Immunometabolism Modulation in Therapy.
Monferrer E, Sanegre S, Vieco-Martí I, López-Carrasco A, Fariñas F, Villatoro A, Abanades S, Mañes S, de la Cruz-Merino L, Noguera R, Álvaro Naranjo T. Monferrer E, et al. Among authors: alvaro naranjo t. Biomedicines. 2021 Jul 9;9(7):798. doi: 10.3390/biomedicines9070798. Biomedicines. 2021. PMID: 34356862 Free PMC article. Review.
Integrating the Tumor Microenvironment into Cancer Therapy.
Sanegre S, Lucantoni F, Burgos-Panadero R, de La Cruz-Merino L, Noguera R, Álvaro Naranjo T. Sanegre S, et al. Among authors: alvaro naranjo t. Cancers (Basel). 2020 Jun 24;12(6):1677. doi: 10.3390/cancers12061677. Cancers (Basel). 2020. PMID: 32599891 Free PMC article. Review.
28 results